CLINICAL STUDY

High urinary ACE2 concentrations are associated with severity of glucose intolerance and microalbuminuria

Se Eun Park, Won Jun Kim, Sung Woo Park, Ji Woo Park, Namseok Lee, Cheol-Young Park* and Byung-Soo Youn

Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea and 1AdipoGen, Inc., Room 401, MeetY ouAll Tower Annex B, Incheon Technopark, 7-50 Songdo-dong, Yeonsu-gu, Incheon, 406-840 Republic of Korea

(Correspondence should be addressed to C-Y Park; Email: cydoctor@chol.com; or to B-S Youn; Email: bsyoun@adipogen.com)

*(C-Y Park is now at Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, No. 108 Pyung-Dong, Jongro-Ku, Seoul 110-746, Republic of Korea)

Abstract

Objective: Angiotensin-converting enzyme 2 (ACE2) plays an important role in glucose metabolism and renal function. However, the relationship between ACE2 and hyperglycemia or microalbuminuria has not been established in humans. We investigated whether urinary ACE2 levels are associated with abnormal glucose homeostasis and urinary albumin excretion.

Methods: We developed an ELISA for quantifying ACE2 in urine. The ELISA was used to measure urinary ACE2 levels in 621 subjects with: normal glucose tolerance (NGT; n=77); impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) (n=132); and type 2 diabetes mellitus (T2DM, n=412). Insulin resistance was assessed by homeostasis model assessment for insulin resistance (HOMA-IR) index and urinary albumin excretion by urine albumin-to-creatinine ratio (ACR). Other biochemical and anthropometric parameters were measured.

Results: Urinary ACE2 levels were significantly higher in insulin-resistant subjects with IFG, IGT, and T2DM than in the NGT group (P<0.001). Urinary ACE2 concentrations appeared to correlate with HOMA-IR, fasting blood glucose, triglyceride, high-sensitivity C-reactive protein, serum creatinine, urinary ACR, and systolic blood pressure (all P<0.05). After adjustment for impaired renal function and other metabolic parameters, urinary ACE2 concentration was still associated with a higher risk for T2DM (OR 1.80, 95% CI 1.05–3.08, P=0.02). In addition, urinary ACE2 levels were highly predictive of microalbuminuria after adjusting for clinical risk factors (OR 2.68, 95% CI 1.55–4.64, P<0.001).

Conclusion: Our data suggest that the urinary ACE2 level is closely associated with T2DM and is an independent risk factor for microalbuminuria.

Introduction

The mechanisms involved in the development of type 2 diabetes mellitus (T2DM) and its complications are complex, with a long list of potential derangements in different pathways (1, 2). Both clinical trials and animal models of T2DM have shown that the renin–angiotensin system (RAS) contributes to the development of T2DM and its complications (3). Of clinical relevance, blockade of the RAS prevents new-onset T2DM and reduces the risk of T2DM and its complications (4, 5).

Angiotensin-converting enzyme (ACE) has long been recognized as the key enzyme within the RAS, as it is involved in cleaving angiotensin (Ang) I to form Ang II, which is the main active peptide within the system. ACE2, a first homolog of ACE, is a monooxygenase that preferentially removes carboxy-terminal amino acids from various substrates, including Ang II, Ang I, and apelin (6, 7, 8, 9). ACE2 cleaves Ang II to form Ang-(1–7) (10). Alterations in glucose tolerance and reduced first-phase insulin secretion have been described in ACE2-deficient mice, suggesting a potential role of ACE2 in the development of T2DM (11).

Microalbuminuria is an early marker of diabetic nephropathy and an independent risk factor for cardiovascular disease (12, 13). Previous data have demonstrated that microalbuminuria is associated with insulin resistance in type 2 diabetic patients as well as in nondiabetic individuals (14). Thus, the early identification and treatment of patients at increased risk for microalbuminuria may be important for preventing renal and cardiovascular diseases associated with T2DM. A number of studies have reported a relationship between RAS and proteinuria (15, 16). In the kidney, ACE2 is localized in the proximal tubules and glomerulus (17). Previously, it was reported that renal expression of ACE2 is downregulated in T2DM (18, 19), whereas others showed that ACE2 expression and ACE2
activity were increased in animal models of diabetes (20, 21). Additionally, a positive relationship between urinary mRNA expression of ACE2 and the degree of proteinuria in human type 2 diabetic nephropathy has been reportedly found (22). Soluble ACE2, as well as ACE, can be detected in urine (23). A recent study identified a significant difference in urinary ACE2 levels between subjects with chronic kidney disease (CKD) and healthy subjects (24). Accordingly, ACE2 is important as a potential participant in the development of both T2DM and nephropathy (25). However, a relationship between urinary concentrations of ACE2 and glycemia or microalbuminuria has not been established.

In this study, we investigated the relationships of urinary ACE2 concentrations with glucose metabolism and urinary albumin excretion status. To further evaluate the role of urinary ACE2, we assessed the relationships between urinary ACE2 levels and various metabolic parameters.

Materials and methods

Participants

Between September 2007 and September 2008, subjects aged 21–80 years with a history of hyperglycemia (fasting plasma glucose ≥ 5.5 mmol/l) or T2DM were enrolled in the Seoul Metro-City Diabetes Prevention Program (SMC-DPP) (26). The subjects were recruited from five public health centers. After exclusion of subjects taking antiobesity medications or corticosteroids and those with histories of diabetic ketoacidosis, symptomatic heart failure, and renal or hepatic dysfunction, assignment to one of the groups was performed using a 75 g oral glucose tolerance test according to the diagnostic criteria of the American Diabetes Association (27). We recruited 621 subjects with: normal glucose tolerance (NGT); impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or IFG+IGT; or T2DM who had adequate, stable renal function (serum creatinine (Cr) < 2.0 mg/dl). All participants provided written informed consent. This study was approved by the Institutional Review Board at Kangbuk Samsung Hospital.

Anthropometric and laboratory measurements

BMI (kg/m²) was calculated as body weight in kilograms divided by height in meters squared. Blood pressures were measured using a sphygmomanometer (Welch Allyn, Inc., Vital Signs Monitor 300 series, Skaneateles Falls, NY, USA) between 0800 and 1000 h after at least 5 min of rest, according to the Hypertension Detection and Follow-up Program protocol (28). Trained nurses measured seated blood pressure. When the SBP or DBP exceeded 140 or 90 mmHg, it was remeasured after a 5-min rest, and the results averaged.

Blood samples were collected following an overnight fast. The subjects also provided the first morning specimen of urine. Aliquots of both plasma and urine were stored at −80 °C until assayed. Height, weight, and waist circumferences were measured. Plasma glucose concentrations were determined using a Beckman glucose analyzer II (Beckman Instruments, Fullerton, CA, USA). HbA1c was measured using HPLC (Variant II, Bio-Rad Laboratories). The assay coefficient of variability (CV) for glucose was < 1.5 and < 3.0% for HbA1c. Serum insulin levels were measured using an immunoradiometric assay (Bio-source, Nivelles, Belgium) following the manufacturer’s recommendations. Plasma lipids, including total cholesterol, triglyceride, HDL-C, and ILDL-C, were measured by enzymatic colorimetric assay (Siemens, Tarrytown, NY, USA). Serum high-sensitivity C-reactive protein (hsCRP) levels were measured by nephelometric assay using a BNII nephelometer (Dade Behring, Deerfield, IL, USA), and the detection limit was 0.175 mg/l with a sample dilution of 1:20. Homeostasis model assessment for insulin resistance (HOMA-IR) was calculated as described previously (29). Serum creatinine was measured using the timed-end point method (Unicel DxC 800, Beckman and Coulter, Krefeld, Germany).

Urinary albumin-to-creatinine ratio (ACR) was calculated using consecutive morning and daytime urine specimens by an immunonephelometric method using the DCA 2000 albumin/creatinine ratio urinalyzer (Bayer Corp.). The intra-assay and interassay CV were reported as being within the range 2 and 8% for ACR. Microalbuminuria was defined as an ACR of 30–300 μg/mg creatinine. Glomerular filtration rate was estimated by the Modification of Diet in Renal Disease (MDRD) Study Group formula (estimated glomerular filtration rate, eGFR). In accordance with the National Kidney Foundation Disease Outcomes Quality Initiative classification system, CKD was defined on the basis of eGFR and categorized into three groups defined by the cutoff points. Therefore, subjects in the stage 1–2 CKD group had eGFRs ≥ 60 ml/min per 1.73 m², the stage 3 CKD group had eGFRs < 60 to ≥ 30 ml/min per 1.73 m², and the stage 4–5 CKD group had eGFRs < 30 ml/min per 1.73 m² (30). Subjects with an eGFR ≥ 90 ml/min per 1.73 m² without proteinuria or history of kidney disease were placed in stage 0.

Development of human ACE2 ELISA and measurement of urinary ACE2 concentrations

A cDNA sequence encoding the original signal peptide sequence and the mature peptide of human ACE2, excluding the transmembrane domain, and a short stretch of cytoplasmic tail, was amplified with the
following primer set: i) forward primer 5’-ctagctagggg-
gacagtcatctt-3’ and ii) reverse primer 5’-cgcctcagggctcgaga
ctaag-3’. The sequence was then digested with NheI and Xhol and cloned into both pAGCF (AdipoGen, Incheon, Korea). A FLAG tag was incorporated at the COOH terminus of the human ACE2 peptide. The tagged protein was expressed in a human embryonic kidney cell line, HEK-293, and purified from conditioned media through an anti-
FLAG sepharose column. Polyclonal antibody (PAb) was then produced by immunization with recombinant
FLAG-tagged human ACE2 according to a general protocol. Immunoglobulin fractions were prepared from serum and then biotinylated. FLAG-tagged ACE2 was used as the ELISA standard at a variety of dilutions. A sandwich ELISA format was designed using a pair of
PAb and biotinylated PAb. One hundred microliters of the biotinylated PAb at 5 mg/ml were added per well. The secondary antibody reaction was performed at 37
°C for 1 h, followed by washing three times with PBS with 0.05% Tween 20
(PBST). One hundred microliters of the biotinylated PAb at 5 mg/ml were added per well. The secondary
antibody reaction was performed at 37°C for 1 h, followed by washing three times with PBST. A colorimetric reaction was conducted for 20 min using
HRP-conjugated streptavidin (Zymed, South San Francisco, CA, USA) diluted 1:1000 in PBS and 2,2'-azino-
bis(2-ethylbenzothiazoline-6-sulfonic acid) (Pierce, Rockford, IL, USA) as the substrate. The optical density
was measured at 450 nm; its sensitivity was 293 pg/ml. While the degree of precision of the ELISA system in
terms of the intra-assay CV was between 6.1 and 9.9%
(Supplementary Table 1, see section on supplementary
data given at the end of this article), the inter-assay CV
were between 5.4 and 10.8% (Supplementary Table 2).
Spice recovery (Supplementary Table 3) and linearity
(Supplementary Table 4) were in the ranges of 90–100
and 89–107%, respectively. Specificity was determined
such that it would not cross-react with human ACE1,
mouse ACE2, human adiponectin, human leptin,
human resistin, human visfatin, human clusterin,
human retinal binding protein 4, human resistin-like
molecule-α (RELM-α), human IL23, human angiopoiet-
in 1, human angiopoietin 2, human fatty acid binding
protein 4, human angiopoietin-like protein 6
(ANGPTL6), human plasminogen activator inhibitor-1
(PAI-1), human vaspin, or mouse RELM-β (Supple-
mentary Table 5).

Statistical analysis
Analyses were performed using SPSS for Windows
software (version 17.0; SPSS). We used ANOVA,
Wilcoxon rank sum tests, and Kruskal–Wallis tests for
comparisons of continuous variables and χ² tests for
comparison of categorical variables. Bivariate corre-
alyses between urinary ACE2 and the
metabolic parameters were performed using Pearson’s
correlation analysis. Multivariate logistic regression
analysis was performed to investigate associations
between T2DM or microalbuminuria with urinary
ACE2 levels. P values <0.05 were considered
significant.

Results
Baseline characteristics of the study participants
are shown in Table 1. The mean age (±s.d.) was 59.8
(±12.8) years and 51.4% of the participants were male.
The duration of diabetes in T2DM subjects was 3.1
±5.2 years. With increasing impairment of glucose
metabolism, we detected expected group differences in
age, waist circumference, fasting blood glucose, Hba1c,
total cholesterol, triglyceride, HDL-C, fasting insulin,
insulin sensitivity (HOMA-IR), hsCRP, and blood
pressure values. Subjects with T2DM exhibited evidence
of impaired renal function, as indicated by higher serum
Cr, lower eGFR, and urinary ACR values. There were
significant differences in urinary ACE2 concentrations
between subjects with NGT, IFG, or IGT and T2DM
(all P<0.05). Among the subjects, 41.7, 40.4, 15.5,
and 20.4% had stage 0, 1, 2, and 3 for CKD respectively.
Urinary ACE2 levels were increased according to the
stage of CKD. The median (interquartile range) for
urinary ACE2 was 2.19 (1.30–4.33) for CKD stage 0,
2.58 (1.52–4.14) for CKD stage 1, 3.78 (2.12–6.55) for
CKD stage 2, and 6.59 (3.54, 9.41) for CKD stage 3
respectively (P<0.01). After adjusting for age, sex, and
BMI, urinary ACE2 concentrations were correlated with
fasting blood glucose, triglyceride, HOMA-IR, hsCRP,
systolic blood pressure, serum Cr, and urinary ACR
levels (Table 2, all P<0.05).

Urinary ACE2 levels were grouped into tertiles to
simplify interpretation of the results of subsequent
analyses. With respect to metabolic parameters, sub-
jects in the higher ACE2 tertiles exhibited higher values
for age, fasting blood glucose, Hba1c, triglyceride,
HOMA-IR, hsCRP, systolic blood pressure, serum Cr,
and urinary ACR (all P<0.05) than those in the lower
tertile (Table 3).

As shown in Table 4, increased urinary ACE2
concentrations were associated with an increased risk
of hyperglycemia. Subjects with a higher level of
urinary ACE2 had a higher risk of T2DM after
adjusting for age, sex, BMI, and several metabolic
parameters (OR 1.80, 95% CI 1.05–3.08, P=0.033).
The corresponding OR for both impaired glucose
regulation (IFG or IGT) and T2DM was 1.88 (95% CI
1.01–3.47, P=0.045).

Multivariate linear regression analysis also showed
that urinary ACE2 concentrations were associated with
a high risk of microalbuminuria (OR 2.68, 95% CI
1.55–4.64, P<0.001) even after controlling for clinical
risk factors (Table 5).
Table 1 Baseline characteristics of the study sample. Data are summarized as mean ± s.d., median (interquartile range) for non-normal distribution, or n (%). HbA1c is expressed as % and mmol/l.

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>NGT (n=77)</th>
<th>IFG or IGT (n=132)</th>
<th>T2DM (n=412)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>41.3 ± 10.2</td>
<td>58.8 ± 12.4</td>
<td>63.5 ± 10.1</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>60/17</td>
<td>60/72</td>
<td>199/213</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>22.7 ± 3.3</td>
<td>24.6 ± 3.3</td>
<td>25.5 ± 11.4</td>
<td>0.056</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>78.4 ± 9.9</td>
<td>84.4 ± 11.5</td>
<td>88.1 ± 15.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fasting blood glucose (mmol/l)</td>
<td>5.30 ± 0.60</td>
<td>6.31 ± 0.59</td>
<td>8.39 ± 2.13</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Urinary ACR (mg/g)</td>
<td>6.0 (5.0–10.8)</td>
<td>11.5 (6.9–32.0)</td>
<td>23.3 (9.8–63.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>hsCRP (mg/l)</td>
<td>0.06 (0.04–0.10)</td>
<td>0.06 (0.03–0.13)</td>
<td>0.09 (0.04–0.22)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fasting insulin (pmol/l)</td>
<td>39.6 (25.2–53.5)</td>
<td>63.3 (51.1–82.0)</td>
<td>72.9 (57.2–99.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HDL-C (mmol/l)</td>
<td>1.38 ± 0.31</td>
<td>1.37 ± 0.32</td>
<td>1.28 ± 0.34</td>
<td>0.005</td>
</tr>
<tr>
<td>LDL-C (mmol/l)</td>
<td>2.84 ± 0.78</td>
<td>2.90 ± 0.83</td>
<td>2.71 ± 0.85</td>
<td>0.064</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>4.66 ± 0.79</td>
<td>0.51 ± 0.94</td>
<td>4.87 ± 0.98</td>
<td>0.007</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>0.90 (0.55–1.48)</td>
<td>1.36 (0.98–1.81)</td>
<td>1.52 (1.08–2.22)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HOMA-IR (arbitrary unit)</td>
<td>2.07 (1.53–2.85)</td>
<td>2.52 (2.02–3.48)</td>
<td>3.90 (2.92–5.30)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>hsCRP (mg/l)</td>
<td>0.06 (0.04–0.10)</td>
<td>0.06 (0.03–0.13)</td>
<td>0.09 (0.04–0.22)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Taking antihypertensive drugs, n (%)</td>
<td>2 (2.6)</td>
<td>49 (37.1)</td>
<td>245 (59.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>114.1 ± 10.8</td>
<td>128.9 ± 9.4</td>
<td>133.6 ± 18.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>70.9 ± 8.3</td>
<td>83.7 ± 2.8</td>
<td>83.4 ± 12.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Urinary ACR (mg/g)</td>
<td>6.0 (5.0–10.8)</td>
<td>11.5 (6.9–32.0)</td>
<td>23.3 (9.8–63.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Serum creatinine concentration (mg/dl)</td>
<td>0.85 ± 0.19</td>
<td>0.74 ± 0.20</td>
<td>0.78 ± 0.20</td>
<td>0.001</td>
</tr>
<tr>
<td>eGFR (ml/min per 1.73 m²)</td>
<td>100.0 ± 22.4</td>
<td>92.5 ± 29.5</td>
<td>82.9 ± 26.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Urinary ACE2 (ng/ml)</td>
<td>2.18 (1.38–3.70)</td>
<td>2.44 (1.33–3.96)</td>
<td>3.00 (1.61–4.97)</td>
<td>0.002</td>
</tr>
<tr>
<td>Current smoking (%)</td>
<td>2 (2.6)</td>
<td>13 (9.8)</td>
<td>59 (14.3)</td>
<td>0.010</td>
</tr>
<tr>
<td>Current alcohol intake (%)</td>
<td>5 (6.5)</td>
<td>52 (39.4)</td>
<td>11.9 (28.9)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

NGT, normal glucose tolerance; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; T2DM, type 2 diabetes mellitus; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate.

Discussion

This study demonstrated that urinary ACE2 levels appear to be elevated in subjects with T2DM and are associated with various metabolic parameters. We also found that urinary ACE2 levels are associated with a higher risk of microalbuminuria, independent of various confounding factors. The results of this study imply that urinary ACE2 concentration may be a valuable marker for both glucose intolerance and microalbuminuria.

Previous studies suggest that ACE2 may play a pivotal role in T2DM. Ang II can delay insulin secretion and reduce blood flow in the islets of Langerhans in rodents. Consistent with this effect of Ang II, blockade of the RAS with either ACE inhibitors or Ang II receptor blockers increases islet blood flow (31). These findings are particularly relevant given clinical evidence that RAS blockade may be associated with reduced incidence of new-onset T2DM (32). ACE2 is elevated in T2DM and may be involved in a compensatory mechanism opposing the ACE/Ang II/AT1 receptor axis, leading to improved glucose tolerance in animal models (3). We therefore hypothesized that urinary ACE2 concentrations are closely related to glucose intolerance and metabolic parameters.

We developed an ELISA for the measurement of human urinary ACE2 concentrations. Takahashi et al. (33) employed an immunoprecipitation technology for...
Table 3 Metabolic risk factors according to urinary ACE2 tertile. Data are summarized as mean ± S.D., median (interquartile range) for non-normal distribution.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>I (n=207)</th>
<th>II (n=209)</th>
<th>III (n=205)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>≤1.92 ng/ml</td>
<td>1.93–3.76 ng/ml</td>
<td>≥3.77 ng/ml</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>58.9 ± 12.3</td>
<td>58.7 ± 13.1</td>
<td>61.7 ± 12.9</td>
<td>0.030</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>92/115</td>
<td>112/97</td>
<td>115/90</td>
<td>0.045</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.7 ± 15.7</td>
<td>24.6 ± 3.3</td>
<td>24.6 ± 3.4</td>
<td>0.372</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>83.5 ± 16.3</td>
<td>85.4 ± 12.4</td>
<td>85.4 ± 14.3</td>
<td>0.330</td>
</tr>
<tr>
<td>Fasting blood glucose (mmol/l)</td>
<td>7.28 ± 1.73</td>
<td>7.39 ± 2.02</td>
<td>8.02 ± 2.51</td>
<td>0.001</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>6.6 ± 1.24</td>
<td>6.77 ± 1.34</td>
<td>7.17 ± 1.50</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>4.99 ± 0.93</td>
<td>4.86 ± 0.94</td>
<td>4.83 ± 1.01</td>
<td>0.212</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.29 (0.94–1.79)</td>
<td>1.47 (0.96–2.24)</td>
<td>1.46 (1.08–2.16)</td>
<td>0.008</td>
</tr>
<tr>
<td>HDL-C (mmol/l)</td>
<td>1.35 ± 0.32</td>
<td>1.30 ± 0.33</td>
<td>1.28 ± 0.34</td>
<td>0.084</td>
</tr>
<tr>
<td>LDL-C (mmol/l)</td>
<td>2.85 ± 0.82</td>
<td>2.78 ± 0.86</td>
<td>2.67 ± 0.85</td>
<td>0.129</td>
</tr>
<tr>
<td>Fasting insulin (pmol/l)</td>
<td>66.4 (50.3–64.7)</td>
<td>67.9 (50.9–94.6)</td>
<td>70.0 (52.2–88.3)</td>
<td>0.432</td>
</tr>
<tr>
<td>HOMA-IR (arbitrary unit)</td>
<td>3.26 (2.41–4.46)</td>
<td>3.64 (2.45–5.08)</td>
<td>3.67 (2.72–4.72)</td>
<td>0.048</td>
</tr>
<tr>
<td>hsCRP (ng/l)</td>
<td>0.07 (0.03–0.17)</td>
<td>0.07 (0.03–0.17)</td>
<td>0.10 (0.05–0.21)</td>
<td>0.003</td>
</tr>
<tr>
<td>Taking antihypertensive drugs, n (%)</td>
<td>83 (40.1)</td>
<td>95 (45.5)</td>
<td>118 (57.6)</td>
<td>0.001</td>
</tr>
<tr>
<td>ACE/ARB (%)</td>
<td>30 (14.5)</td>
<td>34 (16.3)</td>
<td>38 (18.5)</td>
<td>0.540</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>129.0 ± 18.8</td>
<td>128.3 ± 18.2</td>
<td>133.3 ± 20.0</td>
<td>0.017</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>82.2 ± 12.3</td>
<td>81.1 ± 2.6</td>
<td>82.6 ± 12.6</td>
<td>0.441</td>
</tr>
<tr>
<td>Urinary ACR (mg/g)</td>
<td>11.3 (6.6–31.5)</td>
<td>14.2 (7.1–43.8)</td>
<td>24.8 (9.0–97.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Serum creatinine concentration (mg/dl)</td>
<td>0.75 ± 0.19</td>
<td>0.79 ± 0.19</td>
<td>0.82 ± 0.23</td>
<td>0.005</td>
</tr>
<tr>
<td>eGFR (ml/min per 1.73 m²)</td>
<td>88.8 ± 26.8</td>
<td>88.3 ± 26.5</td>
<td>84.1 ± 29.8</td>
<td>0.179</td>
</tr>
</tbody>
</table>

HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; ACE/ARB angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate.

detection of serum ACE2 after removing nucleic acids with the use of an antihuman ACE2 antibody. In parallel with the use of our urinary ACE2 immunoassay, Mizuiri et al. (24) concentrated human sera after removing serum IgG and was able to detect serum ACE2. Regarding the measurement of human ACE2, Dilauro et al. (34) utilized a fluorescence dye-based enzymatic assay that was distinguished from ACE. Recently, Xiao et al. (35) described the presence of urinary ACE2 using an effective western blot analysis in comparison with the current immunoassay and mRNA expression levels, in human urine samples and tissues of a group of diabetic patients with renal transplant. This study showed that both the current ELISA and the western blot were the far more reliable means for measuring the presence of urinary ACE2 than the enzymatic activities in terms of statistics, suggesting that the current ELISA can be more widely and safely applied to measurement of urinary ACE2.

In the current study, urinary ACE2 concentrations were elevated in patients with glucose intolerance and positively related to fasting blood glucose, suggesting that elevated urinary ACE2 might reflect the severity of glucose intolerance. This is the first study to demonstrate that urinary ACE2 levels might reflect the severity of glucose intolerance. We also found that urinary ACE2 concentrations are correlated with metabolic parameters and the insulin resistance index assessed by HOMA-IR. Recently, Ang-(1–7) binding to the Mas receptor was shown to inhibit Ang II responses (36). Santos et al. (37) reported that Mas−/− mice exhibit impaired insulin sensitivity and glucose tolerance, reduced adipose glucose uptake, and impaired glucose transporter 4, which implies that the ACE2/Ang-(1–7)/Mas receptor axis is closely related to the development of insulin resistance. Although the precise mechanisms explaining the role of ACE2 in glucose metabolism are not understood, the link between ACE2 and insulin

Table 4 Risk of type 2 diabetes mellitus with an increase in log(urinary ACE2 (ng/ml)). Values are ORs (95% CI).

<table>
<thead>
<tr>
<th>Model</th>
<th>Adjustment</th>
<th>Type 2 diabetes mellitus</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1</td>
<td>Unadjusted</td>
<td>1.47 (1.37, 3.40)</td>
<td>0.002</td>
</tr>
<tr>
<td>Model 2</td>
<td>Adjusted for age, sex, current smoking, and current alcohol intake, based on Model 1</td>
<td>1.92 (1.16, 3.19)</td>
<td>0.011</td>
</tr>
<tr>
<td>Model 3</td>
<td>Further adjusted for BMI, total cholesterol, insulin, and hsCRP, based on Model 2</td>
<td>1.85 (1.08, 3.16)</td>
<td>0.024</td>
</tr>
<tr>
<td>Model 4</td>
<td>Further adjusted for ACE/ARB use, based on Model 3</td>
<td>1.80 (1.05, 3.08)</td>
<td>0.033</td>
</tr>
</tbody>
</table>

hsCRP, high-sensitivity C-reactive protein; ACE/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker.
Model 4 Further adjusted for systolic blood pressure, ACEi/ARB use, and eGFR, based on Model 3

<table>
<thead>
<tr>
<th>Model</th>
<th>Adjustment</th>
<th>Microalbuminuria</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1</td>
<td>Unadjusted</td>
<td>2.68 (1.55, 4.64)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Model 2</td>
<td>Adjusted for age, sex, BMI, current smoking, and current alcohol intake, based on Model 1</td>
<td>2.74 (1.60, 4.67)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Model 3</td>
<td>Further adjusted for total cholesterol, insulin, and hsCRP, based on Model 2</td>
<td>3.15 (1.90, 5.21)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Model 4</td>
<td>Further adjusted for systolic blood pressure, ACEi/ARB use, and eGFR, based on Model 3</td>
<td>3.35 (2.06, 5.45)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

hsCRP, high-sensitivity C-reactive protein; ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; eGFR, estimated glomerular filtration rate.

Table 5 Risk of microalbuminuria associated with an increase in log(urinary ACE2 (ng/ml)). Values are ORs (95%).

resistance and other metabolic parameters could provide one explanation with respect to glucose metabolism.

Additionally, we showed that ACE2 appears to be positively associated with inflammatory cytokines reflected by hsCRP concentrations. Ang II is well known for its pro-inflammatory action (38), while several studies have demonstrated the ability of ACE2 to inhibit these effects in a disease state (39). Increased inflammation contributes to the development of islet dysfunction and loss of islet morphology (40), which is one potential cause of pancreatic β-cell failure (41). It is possible that ACE2 might have a causal role in systemic inflammation related to the development of T2DM. However, it appears that the relationship between urinary ACE2 and T2DM is consistent, independent of the presence of an inflammatory marker. The mechanism remains unclear, but these results suggest that urinary ACE2 might play a direct role in the severity of glucose intolerance through other mechanisms that do not fully overlap with those of the inflammatory pathways. Further studies are needed to determine whether ACE2 plays a causal role in the regulation of glucose metabolism in humans.

Urinary ACE2 levels are associated with microalbuminuria in our study. Additionally, urinary ACE2 levels are increased according to the stage of CKD. Although this study cannot affirm the cellular origin of urinary ACE2 protein, it could originate at least partly from plasma via glomerular filtration, or it could be derived via excretion from renal cells. A recent study reported increased urinary levels of ACE2 in CKD and diabetic nephropathy, whereas there were no differences in serum ACE2 protein expression (24). However, patients with CKD in their study had significant albuminuria, suggesting that ACE2 may have leaked into the urine across the glomerular barrier. ACE2 is shed at its carboxy-terminus from the plasma membrane in cultured human embryonic kidney cells and airway epithelial cells, a process catalyzed by the enzyme ‘α disintegrin and metalloproteinase-17’ (ADAM-17) (42, 43), but evidence for shedding ACE2 in vivo is limited. Other possibility is that ACE2 protein might derive via shedding from cells along the nephron by ADAM-17 activated by high blood glucose (44), which might lead to higher urinary ACE2 levels in subjects with CKD. These inverse relationships between urinary expression of ACE2 and renal function imply that urinary ACE2 expression might be a compensatory response of renal tissue to insults. Therefore, urinary ACE2 concentrations might clinically serve as a marker for microalbuminuria and its possible role as a marker for renal impairment needs to be explored further.

There were several limitations to our study. First, due to the cross-sectional nature of our study, we were not able to examine the temporal relationship between urinary ACE2 levels and the severity of glucose intolerance and related metabolic parameters. Long-term follow-up of larger groups is needed to establish the predictive relationship between urinary ACE2 concentrations and metabolic parameters and renal function. Additionally, our study subjects were not drug-naïve, and some subjects were on antihypertensives, glucose-lowering medications, or both, which could influence both urinary ACE2 concentrations and renal excretion of albumin. However, we did not observe significant differences in the urinary ACE2 levels for subjects undergoing ACE inhibitor or Ang II receptor blocker therapy (P = 0.14, data not shown). Finally, we could not measure the serum levels of ACE2 with the use of the current ELISA assay in our study, likely due to the presence of very low levels of serum ACE2. Evidence for this interpretation was recently provided by Mizuiri et al. (24) in that they were able to detect serum ACE2 in western blot analysis only after 20-fold concentration in subjects whose expression patterns remained unchanged in response to CKD.

Nonetheless, our results suggested that urinary ACE2 levels are elevated in subjects with T2DM and are independently associated with a higher risk of microalbuminuria. We also detected significant relationships between urinary ACE2 concentrations and various metabolic and inflammatory markers. Urinary ACE2 concentrations will provide additional information about the role of kidney RAS and may be useful as a marker of glucose intolerance and renal dysfunction among subjects with CKD. Hence, it may be useful as a marker of glucose intolerance and renal dysfunction among subjects with CKD. These inverse relationships between urinary expression of ACE2 and renal function imply that urinary ACE2 expression might be a compensatory response of renal tissue to insults. Therefore, urinary ACE2 concentrations might clinically serve as a marker for microalbuminuria and its possible role as a marker for renal impairment needs to be explored further.

There were several limitations to our study. First, due to the cross-sectional nature of our study, we were not able to examine the temporal relationship between urinary ACE2 levels and the severity of glucose intolerance and related metabolic parameters. Long-term follow-up of larger groups is needed to establish the predictive relationship between urinary ACE2 concentrations and metabolic parameters and renal function. Additionally, our study subjects were not drug-naïve, and some subjects were on antihypertensives, glucose-lowering medications, or both, which could influence both urinary ACE2 concentrations and renal excretion of albumin. However, we did not observe significant differences in the urinary ACE2 levels for subjects undergoing ACE inhibitor or Ang II receptor blocker therapy (P = 0.14, data not shown). Finally, we could not measure the serum levels of ACE2 with the use of the current ELISA assay in our study, likely due to the presence of very low levels of serum ACE2. Evidence for this interpretation was recently provided by Mizuiri et al. (24) in that they were able to detect serum ACE2 in western blot analysis only after 20-fold concentration in subjects whose expression patterns remained unchanged in response to CKD.

Nonetheless, our results suggested that urinary ACE2 levels are elevated in subjects with T2DM and are independently associated with a higher risk of microalbuminuria. We also detected significant relationships between urinary ACE2 concentrations and various metabolic and inflammatory markers. Urinary ACE2 concentrations will provide additional information about the role of kidney RAS and may be useful as a marker of glucose intolerance and renal dysfunction among subjects with CKD. Hence, it may be useful as a marker of glucose intolerance and renal dysfunction among subjects with CKD.
Supplementary data

This is linked to the online version of the paper at http://dx.doi.org/10.1530/EJE-12-0782.

Declaration of interest

J W Park, N Lee, and B-S Youn are employees of AdipoGen, Inc. The other authors have nothing to disclose.

Funding

This work was supported by AdipoGen, Inc.; Health Promotion Funds from the Korean Ministry for Health, Welfare, and Family Affairs; and the Welfare Bureau of the Seoul Metropolitan Government.

References

29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and

www.eje-online.org


Received 2 May 2012
Revised version received 29 October 2012
Accepted 8 November 2012